News

Global Chronic Obstructive Pulmonary Disease Treatment Devices Market To Witness Growth At A CAGR Of ~6% By 2032 Delveinsight
The market for chronic obstructive pulmonary disease treatment devices is projected to witness substantial growth, fueled by ...
Regeneron Earnings Call: Growth Amid Challenges
Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Q2 2025 Earnings Call Transcript
Q2 2025 Earnings Call Transcript August 1, 2025 Regeneron Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is ...
Regeneron: Rapidly Decreasing Importance Of Eylea
Regeneron Pharmaceuticals delivered strong Q2 results and made net progress with its commercial portfolio and pipeline. Click ...
Regeneron outlines path to $17B Dupixent annual sales and initiates 10 Lynozyfic registrational trials amid robust Q2 growth
Q2 2025 Management View CEO Leonard S. Schleifer reported "Regeneron delivered a strong second quarter, driven by durable ...
Why Regeneron (REGN) Stock Is Trading Up Today
Shares of biotech company Regeneron (NASDAQ:REGN) jumped 3.3% in the morning session after the company reported strong second-quarter financial results that significantly surpassed analyst ...
Regeneron beats second-quarter results estimates on Dupixent sales boost
Sales of the anti-inflammatory drug rose 22% to $4.34 billion, compared with an estimate of $4.14 billion. The Tarrytown, New ...
Regeneron Reports Second Quarter 2025 Financial and Operating Results
Second quarter 2025 revenues increased 4% to $3.68 billion versus second quarter 2024Dupixent® global net sales (recorded by Sanofi) increased 22% to $4.34 billion EYLEA HD® U.S. net sales increased ...